224 related articles for article (PubMed ID: 37276407)
1. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407
[TBL] [Abstract][Full Text] [Related]
2. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
3. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
4. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
5. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
6. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
Verkhivker G
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
[TBL] [Abstract][Full Text] [Related]
7. Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics.
Panda M; Kalita E; Singh S; Kumar K; Prajapati VK
Mol Divers; 2023 Dec; 27(6):2577-2603. PubMed ID: 36400898
[TBL] [Abstract][Full Text] [Related]
8. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
9. Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2.
Cross FR; Fridy PC; Ketaren NE; Mast FD; Li S; Olivier JP; Pecani K; Chait BT; Aitchison JD; Rout MP
J Biol Chem; 2023 Mar; 299(3):102954. PubMed ID: 36720309
[TBL] [Abstract][Full Text] [Related]
10. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
Verkhivker G
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
[TBL] [Abstract][Full Text] [Related]
11. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.
Pymm P; Redmond SJ; Dolezal O; Mordant F; Lopez E; Cooney JP; Davidson KC; Haycroft ER; Tan CW; Seneviratna R; Grimley SL; Purcell DFJ; Kent SJ; Wheatley AK; Wang LF; Leis A; Glukhova A; Pellegrini M; Chung AW; Subbarao K; Uldrich AP; Tham WH; Godfrey DI; Gherardin NA
iScience; 2022 Nov; 25(11):105259. PubMed ID: 36213007
[TBL] [Abstract][Full Text] [Related]
12. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.
Zupancic JM; Desai AA; Schardt JS; Pornnoppadol G; Makowski EK; Smith MD; Kennedy AA; Garcia de Mattos Barbosa M; Cascalho M; Lanigan TM; Tai AW; Tessier PM
Cell Chem Biol; 2021 Sep; 28(9):1379-1388.e7. PubMed ID: 34171229
[TBL] [Abstract][Full Text] [Related]
13. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
Chen X; Gentili M; Hacohen N; Regev A
Nat Commun; 2021 Sep; 12(1):5506. PubMed ID: 34535642
[TBL] [Abstract][Full Text] [Related]
14. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
Jiang X; Qin Q; Zhu H; Qian J; Huang Q
Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
[TBL] [Abstract][Full Text] [Related]
18. Identification of Human Single-Domain Antibodies against SARS-CoV-2.
Wu Y; Li C; Xia S; Tian X; Kong Y; Wang Z; Gu C; Zhang R; Tu C; Xie Y; Yang Z; Lu L; Jiang S; Ying T
Cell Host Microbe; 2020 Jun; 27(6):891-898.e5. PubMed ID: 32413276
[TBL] [Abstract][Full Text] [Related]
19. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift.
Laroche A; Orsini Delgado ML; Chalopin B; Cuniasse P; Dubois S; Sierocki R; Gallais F; Debroas S; Bellanger L; Simon S; Maillère B; Nozach H
MAbs; 2022; 14(1):2076775. PubMed ID: 35593235
[TBL] [Abstract][Full Text] [Related]
20. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.
Walter JD; Scherer M; Hutter CAJ; Garaeva AA; Zimmermann I; Wyss M; Rheinberger J; Ruedin Y; Earp JC; Egloff P; Sorgenfrei M; Hürlimann LM; Gonda I; Meier G; Remm S; Thavarasah S; van Geest G; Bruggmann R; Zimmer G; Slotboom DJ; Paulino C; Plattet P; Seeger MA
EMBO Rep; 2022 Apr; 23(4):e54199. PubMed ID: 35253970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
